

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 40D0693411	(X3) Date Survey Completed 03/17/2022
Name of Provider or Supplier Lab Garcia, Corp	Street Address, City, State Calle 65 Infanteria #67, Anasco, PR	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D5403	<p>PROCEDURE MANUAL CFR(s): 493.1251(b)</p> <p>The procedure manual must include the following when applicable to the test procedure: (1) Requirements for patient preparation; specimen collection, labeling, storage, preservation, transportation, processing, and referral; and criteria for specimen acceptability and rejection as described in 493.1242. (2) Microscopic examination, including the detection of inadequately prepared slides. (3) Step-by-step performance of the procedure, including test calculations and interpretation of results. (4) Preparation of slides, solutions, calibrators, controls, reagents, stains, and other materials used in testing. (5) Calibration and calibration verification procedures. (6) The reportable range for test results for the test system as established or verified in 493.1253. (7) Control procedures. (8) Corrective action to take when calibration or control results fail to meet the laboratory's criteria for acceptability. (9) Limitations in the test methodology, including interfering substances. (10) Reference intervals (normal values). (11) Imminently life-threatening test results, or panic or alert values. (12) Pertinent literature references. (13) The laboratory's system for entering results in the patient record and reporting patient results including, when appropriate, the protocol for reporting imminently life threatening results, or panic, or alert values. (14) Description of the course of action to take if a test system becomes inoperable.</p> <p>This STANDARD is not met as evidenced by: Based on Immuno Card Mycoplasma manufacturer's instructions, Mycoplasma testing records review from January 5, 2021 to December 29, 2021 and laboratory testing personnel and general supervisor interview, it was determined that the laboratory failed to follow the manufacturer's instruction when 74 out of 74 patient's specimens were tested for Mycoplasma by Immuno Card Meridian method from January 5, 2021 to December 29, 2021. The findings include: 1. The manufacturer's instruction establishes to perform the test procedures at room temperature from 22C to 25C. 2. On March 17, 2022 at 10:58 AM, the Mycoplasma testing records showed that the</p>

laboratory did not monitor nor record the mycoplasma testing room temperature when patient's specimens were tested for Mycoplasma by Immuno Card Meridian method from January 5, 2021 to December 29, 2021. 3. The laboratory testing personnel and general supervisor confirmed on March 17, 2022 at 11:12 AM, that the laboratory did not follow the manufacture's instructions for the temperature of processing. 4. The laboratory processed and reported 74 out of 74 patients specimens for mycoplasma test by Immuno Card Meridian method from January 5, 2021 to December 29, 2021.

D6020

LABORATORY DIRECTOR RESPONSIBILITIES
CFR(s): 493.1407(e)(5)

The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(5) Ensure that the quality control program is established and maintained to assure the quality of laboratory services provided.

This STANDARD is not met as evidenced by:
Based on Immuno Card Mycoplasma manufacturer's instructions, Mycoplasma testing records review from January 5, 2021 to December 29, 2021, laboratory testing personnel and general supervisor interview on March 17, 2022 at 11:54 AM, it was determined that the laboratory director failed to ensure that the laboratory follow the manufacturer's instruction for monitor and documented the room temperature when the patient's specimens were tested for Mycoplasma by Immuno Card Meridian method. Refer to D5403.

D6070

TESTING PERSONNEL RESPONSIBILITIES
CFR(s): 493.1425(b)(1)

Each individual performing moderate complexity testing must follow the laboratory's procedures for specimen handling and processing, test analyses, reporting and maintaining records of patient test results.

This STANDARD is not met as evidenced by:
Based on Immuno Card Mycoplasma manufacturer's instructions, Mycoplasma testing records review from January 5, 2021 to December 29, 2021, laboratory testing personnel and general supervisor interview on March 17, 2022 at 10:58 AM, it was determined that the testing personnel failed to follow the manufacturer's instruction when patient's were tested for Mycoplasma by Immuno Card Meridian Method from January 5, 2021 to December 29, 2021. Refer to D5403.